Back to All Events

Sunvou FeNO & Sanofi Dupixent Drug Collaboration

"Sunvou and Sanofi Collaborate to Advance Precision Diagnosis and Treatment for Asthma Patients"

During the exhibition, Sunvou Medical, in collaboration with Sanofi, jointly introduced the “Asthma Patient-Centered Precision Diagnosis and Treatment” cooperation initiative. This initiative reflects a shared commitment to improving asthma care by focusing on more accurate diagnosis and individualized treatment approaches. Despite ongoing advancements in respiratory medicine, asthma control levels worldwide continue to present a significant challenge. In China in particular, approximately 55–70% of asthma patients experience inadequate disease management, placing a considerable burden on both patients and healthcare systems.

At the meeting, Professor Zhou Xin from the First People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine presented the “FeNO Detection and Biological Agents Application Initiative in the Precision Diagnosis and Treatment of Type 2 Asthma.” His presentation emphasized the growing importance of integrating advanced diagnostic tools with targeted therapies in clinical practice. Professor Zhou highlighted that FeNO detection serves as a convenient and non-invasive method, offering valuable clinical insights for both the diagnosis and ongoing management of respiratory diseases.

He further noted that incorporating FeNO testing into routine care can support more precise evaluation of airway inflammation, enabling clinicians to make better-informed treatment decisions. As part of this initiative, the adoption of innovative detection methods alongside optimized treatment strategies is expected to significantly enhance asthma management outcomes.

Overall, the initiative aims to improve disease control rates and reduce the long-term burden associated with asthma. By advancing precision diagnosis and promoting more effective treatment pathways, it is anticipated that airway health can be better protected, ultimately benefiting millions of patients and contributing to improved quality of life on a broader scale.

Previous
Previous
October 18

Prof. Ian Addcock's Visit to Sunvou Headquarters in Wuxi

Next
Next
December 2

Florence International Respiratory Diseases Meeting